Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
US Stock Futures Edge Lower Ahead Of Federal Budget
Morgan Stanley Downgrades Bristol-Myers On Valuation
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters